Cystic Fibrosis - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Cystic Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
To access full report with TOC, please visit Cystic Fibrosis - Pipeline Review, H1 2016.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Actelion Ltd Akari Therapeutics, Plc Alaxia SAS AlgiPharma AS AmpliPhi Biosciences Corporation Arcturus Therapeutics, Inc Aridis Pharmaceuticals LLC AstraZeneca Plc Bayer AG Boehringer Ingelheim GmbH Calista Therapeutics, Inc. Carolus Therapeutics, Inc. Celtaxsys, Inc. Chiesi Farmaceutici SpA Cilian AG Concert Pharmaceuticals, Inc. Corbus pharmaceuticals, Inc. CSA Biotechnologies LLC Cyclacel Pharmaceuticals, Inc. DiscoveryBiomed, Inc. Editas Medicine, Inc. Errant Gene Therapeutics, LLC Galapagos NV GlaxoSmithKline Plc Grifols, S.A. Grupo Praxis Pharmaceutical SA Horizon Pharma Plc Insmed Incorporated Invion Limited JHL Biotech, Inc. Kamada Ltd. La Jolla Pharmaceutical Company Lamellar Biomedical Ltd Laurent Pharmaceuticals Inc. Mast Therapeutics, Inc. Merck & Co., Inc. Microbion Corporation Mucokinetica Ltd. NanoBio Corporation Nivalis Therapeutics, Inc. Nostrum Pharmaceuticals, LLC Novabiotics Limited Novartis AG OSE Pharma SA Parion Sciences, Inc. Pfizer Inc. Pharmaxis Limited PhaseBio Pharmaceuticals, Inc. Polyphor Ltd. Progenra, Inc. ProMetic Life Sciences Inc. ProQR Therapeutics N.V. Protalix BioTherapeutics, Inc. Proteostasis Therapeutics, Inc. PTC Therapeutics, Inc. Pulmatrix, Inc. Raptor Pharmaceutical Corp. ReveraGen BioPharma, Inc. Savara Inc. Serendex Pharmaceuticals A/S Shionogi & Co., Ltd. Shire Plc Synovo GmbH TGV-Laboratories The International Biotechnology Center (IBC) Generium Verona Pharma Plc Vertex Pharmaceuticals Incorporated Xenetic Biosciences (UK) Limited Zambon Company S.p.A.
Manager - Marketing
Reportstack Market Research